{'fraction_non_alphanumeric': 0.02108433734939759, 'fraction_numerical': 0.002008032128514056, 'mean_word_length': 5.310126582278481, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[The place of thiazolidinediones in the treatment of type 2 diabetes].

SUPPLEMENTARY ORAL ANTIDIABETICS: Thiazolidinediones or glitazones are a new class of oral antidiabetics, the effects on blood sugar control of which are mediated by the sensitivity of the peripheral tissue to the effect of insulin. Hence, their effect is complementary to that of the insulin secreting agents and that of metformin, which acts by blocking the hepatic production of glucose. OTHER BENEFICIAL EFFECTS: Other than their effect on blood glucose, thiazolidinediones have a favorable influence upon the cardiovascular risk factors or markers such as blood pressure, C-reactive protein and metalloproteinase-9. They also appear to induce long term preservation of the beta-cell capital. Principle side effects are salt-water retention with a risk of decompensation of a pre-existing heart failure and weight gain with regard to the subcutaneous adipose tissue, without deleterious effects on blood glucose control.